S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
Log in
NYSE:CHE

Chemed Competitors

$445.21
-1.14 (-0.26 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$437.75
Now: $445.21
$451.76
50-Day Range
$446.69
MA: $517.22
$556.02
52-Week Range
$330.01
Now: $445.21
$560.00
Volume177,411 shs
Average Volume99,339 shs
Market Capitalization$7.10 billion
P/E Ratio27.00
Dividend Yield0.30%
Beta0.55

Competitors

Chemed (NYSE:CHE) Vs. LH, DGX, DVA, AMED, LHCG, and AMN

Should you be buying CHE stock or one of its competitors? Companies in the sub-industry of "health care services" are considered alternatives and competitors to Chemed, including Laboratory Co. of America (LH), Quest Diagnostics (DGX), DaVita (DVA), Amedisys (AMED), LHC Group (LHCG), and AMN Healthcare Services (AMN).

Chemed (NYSE:CHE) and Laboratory Co. of America (NYSE:LH) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations for Chemed and Laboratory Co. of America, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Chemed00203.00
Laboratory Co. of America011402.93

Chemed currently has a consensus target price of $557.50, indicating a potential upside of 25.22%. Laboratory Co. of America has a consensus target price of $235.4667, indicating a potential downside of 1.85%. Given Chemed's stronger consensus rating and higher probable upside, analysts plainly believe Chemed is more favorable than Laboratory Co. of America.

Earnings & Valuation

This table compares Chemed and Laboratory Co. of America's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Chemed$1.94 billion3.66$219.92 million$13.9531.91
Laboratory Co. of America$11.55 billion2.02$823.80 million$11.3221.19

Laboratory Co. of America has higher revenue and earnings than Chemed. Laboratory Co. of America is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Chemed and Laboratory Co. of America's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Chemed13.11%38.13%21.70%
Laboratory Co. of America6.79%21.05%8.83%

Insider and Institutional Ownership

86.0% of Chemed shares are held by institutional investors. Comparatively, 89.3% of Laboratory Co. of America shares are held by institutional investors. 4.0% of Chemed shares are held by insiders. Comparatively, 0.7% of Laboratory Co. of America shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Chemed has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. Comparatively, Laboratory Co. of America has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500.

Summary

Chemed beats Laboratory Co. of America on 8 of the 14 factors compared between the two stocks.

Quest Diagnostics (NYSE:DGX) and Chemed (NYSE:CHE) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Analyst Recommendations

This is a breakdown of recent ratings for Quest Diagnostics and Chemed, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Quest Diagnostics09602.40
Chemed00203.00

Quest Diagnostics currently has a consensus target price of $129.00, suggesting a potential upside of 11.60%. Chemed has a consensus target price of $557.50, suggesting a potential upside of 25.22%. Given Chemed's stronger consensus rating and higher probable upside, analysts clearly believe Chemed is more favorable than Quest Diagnostics.

Earnings & Valuation

This table compares Quest Diagnostics and Chemed's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quest Diagnostics$7.73 billion2.00$858 million$6.5617.62
Chemed$1.94 billion3.66$219.92 million$13.9531.91

Quest Diagnostics has higher revenue and earnings than Chemed. Quest Diagnostics is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Quest Diagnostics and Chemed's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Quest Diagnostics13.22%19.23%8.77%
Chemed13.11%38.13%21.70%

Institutional & Insider Ownership

85.7% of Quest Diagnostics shares are held by institutional investors. Comparatively, 86.0% of Chemed shares are held by institutional investors. 1.5% of Quest Diagnostics shares are held by insiders. Comparatively, 4.0% of Chemed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Dividends

Quest Diagnostics pays an annual dividend of $2.24 per share and has a dividend yield of 1.9%. Chemed pays an annual dividend of $1.36 per share and has a dividend yield of 0.3%. Quest Diagnostics pays out 34.1% of its earnings in the form of a dividend. Chemed pays out 9.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Quest Diagnostics has raised its dividend for 1 consecutive years and Chemed has raised its dividend for 12 consecutive years.

Risk & Volatility

Quest Diagnostics has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500. Comparatively, Chemed has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500.

Summary

Chemed beats Quest Diagnostics on 11 of the 17 factors compared between the two stocks.

DaVita (NYSE:DVA) and Chemed (NYSE:CHE) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Analyst Recommendations

This is a breakdown of recent ratings for DaVita and Chemed, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
DaVita04102.20
Chemed00203.00

DaVita currently has a consensus target price of $116.40, suggesting a potential upside of 13.97%. Chemed has a consensus target price of $557.50, suggesting a potential upside of 25.22%. Given Chemed's stronger consensus rating and higher probable upside, analysts clearly believe Chemed is more favorable than DaVita.

Earnings and Valuation

This table compares DaVita and Chemed's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DaVita$11.39 billion0.98$810.98 million$5.4018.91
Chemed$1.94 billion3.66$219.92 million$13.9531.91

DaVita has higher revenue and earnings than Chemed. DaVita is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares DaVita and Chemed's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
DaVita7.32%43.99%5.27%
Chemed13.11%38.13%21.70%

Insider & Institutional Ownership

91.7% of DaVita shares are owned by institutional investors. Comparatively, 86.0% of Chemed shares are owned by institutional investors. 1.0% of DaVita shares are owned by insiders. Comparatively, 4.0% of Chemed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

DaVita has a beta of 1.3, suggesting that its stock price is 30% more volatile than the S&P 500. Comparatively, Chemed has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500.

Summary

Chemed beats DaVita on 9 of the 14 factors compared between the two stocks.

Amedisys (NASDAQ:AMED) and Chemed (NYSE:CHE) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Analyst Recommendations

This is a breakdown of recent ratings for Amedisys and Chemed, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amedisys03902.75
Chemed00203.00

Amedisys currently has a consensus target price of $274.4615, suggesting a potential upside of 8.21%. Chemed has a consensus target price of $557.50, suggesting a potential upside of 25.22%. Given Chemed's stronger consensus rating and higher probable upside, analysts clearly believe Chemed is more favorable than Amedisys.

Earnings and Valuation

This table compares Amedisys and Chemed's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amedisys$1.96 billion4.26$126.83 million$4.4057.65
Chemed$1.94 billion3.66$219.92 million$13.9531.91

Chemed has lower revenue, but higher earnings than Amedisys. Chemed is trading at a lower price-to-earnings ratio than Amedisys, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Amedisys and Chemed's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amedisys8.22%26.41%12.43%
Chemed13.11%38.13%21.70%

Insider & Institutional Ownership

85.9% of Amedisys shares are owned by institutional investors. Comparatively, 86.0% of Chemed shares are owned by institutional investors. 2.8% of Amedisys shares are owned by insiders. Comparatively, 4.0% of Chemed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Amedisys has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Chemed has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500.

Summary

Chemed beats Amedisys on 9 of the 14 factors compared between the two stocks.

LHC Group (NASDAQ:LHCG) and Chemed (NYSE:CHE) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Analyst Recommendations

This is a breakdown of recent ratings for LHC Group and Chemed, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
LHC Group02702.78
Chemed00203.00

LHC Group currently has a consensus target price of $220.00, suggesting a potential upside of 21.07%. Chemed has a consensus target price of $557.50, suggesting a potential upside of 25.22%. Given Chemed's stronger consensus rating and higher probable upside, analysts clearly believe Chemed is more favorable than LHC Group.

Earnings and Valuation

This table compares LHC Group and Chemed's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LHC Group$2.08 billion2.76$95.73 million$4.4740.65
Chemed$1.94 billion3.66$219.92 million$13.9531.91

Chemed has lower revenue, but higher earnings than LHC Group. Chemed is trading at a lower price-to-earnings ratio than LHC Group, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares LHC Group and Chemed's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
LHC Group5.00%9.71%6.51%
Chemed13.11%38.13%21.70%

Insider & Institutional Ownership

91.8% of LHC Group shares are owned by institutional investors. Comparatively, 86.0% of Chemed shares are owned by institutional investors. 4.8% of LHC Group shares are owned by insiders. Comparatively, 4.0% of Chemed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

LHC Group has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500. Comparatively, Chemed has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500.

Summary

Chemed beats LHC Group on 9 of the 14 factors compared between the two stocks.

AMN Healthcare Services (NYSE:AMN) and Chemed (NYSE:CHE) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Insider & Institutional Ownership

94.6% of AMN Healthcare Services shares are owned by institutional investors. Comparatively, 86.0% of Chemed shares are owned by institutional investors. 1.4% of AMN Healthcare Services shares are owned by insiders. Comparatively, 4.0% of Chemed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares AMN Healthcare Services and Chemed's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AMN Healthcare Services$2.22 billion1.54$113.99 million$3.1822.92
Chemed$1.94 billion3.66$219.92 million$13.9531.91

Chemed has lower revenue, but higher earnings than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings for AMN Healthcare Services and Chemed, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AMN Healthcare Services00703.00
Chemed00203.00

AMN Healthcare Services currently has a consensus target price of $76.2857, suggesting a potential upside of 4.69%. Chemed has a consensus target price of $557.50, suggesting a potential upside of 25.22%. Given Chemed's higher probable upside, analysts clearly believe Chemed is more favorable than AMN Healthcare Services.

Profitability

This table compares AMN Healthcare Services and Chemed's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AMN Healthcare Services3.78%20.38%6.87%
Chemed13.11%38.13%21.70%

Volatility & Risk

AMN Healthcare Services has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Comparatively, Chemed has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500.

Summary

Chemed beats AMN Healthcare Services on 9 of the 13 factors compared between the two stocks.


Chemed Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Laboratory Co. of America logo
LH
Laboratory Co. of America
1.6$239.91-1.4%$23.37 billion$11.55 billion27.93
Quest Diagnostics logo
DGX
Quest Diagnostics
2.1$115.59-0.8%$15.43 billion$7.73 billion14.29Insider Selling
DaVita logo
DVA
DaVita
2.0$102.13-0.0%$11.17 billion$11.39 billion15.31
Amedisys logo
AMED
Amedisys
1.2$253.64-3.7%$8.32 billion$1.96 billion50.83Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Down
LHC Group logo
LHCG
LHC Group
1.7$181.71-3.5%$5.74 billion$2.08 billion55.23Earnings Announcement
High Trading Volume
News Coverage
Gap Up
AMN Healthcare Services logo
AMN
AMN Healthcare Services
1.3$72.87-1.1%$3.43 billion$2.22 billion38.97Insider Selling
R1 RCM logo
RCM
R1 RCM
1.6$27.64-0.7%$3.22 billion$1.19 billion307.15Insider Selling
News Coverage
MEDNAX logo
MD
MEDNAX
1.4$24.43-1.9%$2.09 billion$3.51 billion-2.83Analyst Report
Gap Up
The Providence Service logo
PRSC
The Providence Service
1.0$128.26-16.7%$1.82 billion$1.51 billion-2,137.31Gap Down
CorVel logo
CRVL
CorVel
0.8$101.50-0.0%$1.81 billion$592.22 million45.11Insider Selling
News Coverage
Tivity Health logo
TVTY
Tivity Health
1.0$23.80-1.6%$1.16 billion$1.13 billion-2.15Earnings Announcement
Analyst Report
Unusual Options Activity
Analyst Revision
News Coverage
Cross Country Healthcare logo
CCRN
Cross Country Healthcare
1.1$11.11-1.9%$417.33 million$822.22 million-21.37Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Down
Interpace Biosciences logo
IDXG
Interpace Biosciences
1.7$3.25-0.0%$13.18 million$24.08 million-0.38Gap Down
This page was last updated on 2/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.